Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
A
147
A Clinical Quantitative Systems Pharmacology Framework Describing Loncastuximab Tesirine Distribution & to Explore Patient Outcomes from the Lotis-2 Clinical Trial in Patients With B-Cell Lymphomas
Favorite
114
A Clinical Study to Evaluate the Feasibility of Decentralized Clinical Trial Elements in Korean Patients
Favorite
107
A Combined Ex Vivo & Physiologically-based Pharmacokinetic Approach to Determine Fentanyl Dosing in Children on Continuous Renal Replacement Therapy
Favorite
009
A Combined Ex Vivo & Physiologically-based Pharmacokinetic Approach to Determine Fentanyl Dosing in Children on Continuous Renal Replacement Therapy
Favorite
109
A Comparison of Capillary Microsampling Devices Vs Venipuncture in a Single-Dose Clinical Pharmacokinetics Study of Large & Small Molecules
Favorite
144
A Concentration-QT Analysis Identifies No Meaningful Effect of Nirogacestat or Itraconazole on QTcF Interval
Favorite
143
A Meta-Analysis to Understand the Correlation Between Weight Loss & Resolution of Nonalcoholic Steatohepatitis
Favorite
116
A Multi-layer AI Algorithm that Transcribes SDTM Data into Full-length CSR
Favorite
018
A Novel Auto-Injector Design to Maintain Investigator Blinding in Randomised Controlled Trials
Favorite
199
A PBPK-Driven Modeling Approach for Extrapolation of Clinical Pharmacokinetic Results for Oral Nicotine-Containing Products
Favorite
060
A Phase 1 Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma & CSF Pharmacokinetics & QEEG Changes Reflecting Receptor Engagement
Favorite
028
A Phase 1, Open-Label, 4-Part, Drug-Drug Interaction Study With Omaveloxolone in Healthy Subjects
Favorite
187
A Phase 1, Open-label, Single Ascending Dose Study to Evaluate the Pharmacokinetics of Vorasidenib in Healthy Japanese & Non-Asian Participants
Favorite
073
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, 2-Period, Fixed-Sequence Study to Assess the Relative Bioavailability & Safety of Low-Sodium Oxybate Between Japanese & Non-Asian Participants
Favorite
064
A Phase 1b, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics & Safety of Vadadustat in Hemodialysis Patients With Anemia Associated With Chronic Kidney Disease
Favorite
070
A Phase I Study of the Absorption, Metabolism & Excretion Following a Single Oral Dose of [14C]-Adagrasib in Healthy Male Subjects
Favorite
174
A Population Pharmacokinetic Analysis to Evaluate the Effect of Race (Japanese vs Non-Asian) on Exposure of Low-Sodium Oxybate
Favorite
079
A Review of Immunogenicity & Its Effect on Efficacy & Safety of Biologics as Reported on the Prescribing Label to Support Strategic Thinking & Planning Labeling Communications
Favorite
020
A Science-based Approach for Recommendation of Antagonist Blockade in the Bioequivalence Studies of Opioid Drug Products
Favorite
112
A Systemic Examination of Natural Language Processing Algorithms in Longitudinal Pharmacokinetic/Pharmacodynamic Analyses
Favorite
170
A Target-mediated Drug Disposition Model to Explain the Nonlinear Pharmacokinetics of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor BI-187004 in Healthy Subjects
Favorite
138
A Thorough QT Study Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization
Favorite
067
Absolute Oral Bioavailability of Milvexian Spray-dried Dispersion Formulation Under Fasted & Fed Conditions in Healthy Adult Participants Using an Intravenous Microtracer Approach
Favorite
035
Adoption of Patient Reported Outcomes in Early Clinical Trials for Oncology Drugs: Challenges & Opportunities
Favorite
145
An Evaluation of POPPK & PBPK Model-based Virtual Controls to Replace Healthy Subject Controls in Organ Impairment PK Studies
Favorite
040
An Interactive Approach for Evaluation of Monoclonal Antibody Dosing in Light of Rapidly Evolving SARS-CoV-2 Variants
Favorite
068
Anakinra Removal by Continuous Renal Replacement Therapy: An Ex-vivo Analysis
Favorite
011
Analysis of Supervised Machine Learning Algorithms & Computational Validation of the Single Nucleotide Polymorphisms of Antioxidant Enzymes & Oxidative Stress Biomarkers in Preterm Neonates
Favorite
034
Application of Hybrid Pharmacometric/Machine-Learning Approach to Inform Moxifloxacin Therapeutic Drug Monitoring in Children
Favorite
027
Application of Modeling & Simulation to Quantitatively Assess Ulotaront Metabolism & the Effect of a CYP450 Inhibitor in Healthy Subjects
Favorite
045
Applications of Physiologically-based Pharmacokinetic Modeling & Model Based Meta-analysis in Hormonal Contraceptive Breakthrough Bleedings Analysis
Favorite
191
Assessing Pediatric Vancomycin Exposures & the Influences of Body Composition
Favorite
118
Assessment of Anti-Drug Antibody Incidence in Subcutaneously Administered Antibody-Based Therapeutics Approved Between 2010-2022
Favorite
133
Assessment of the Effect of P-gp Inhibition on Pharmacokinetics of the RET Inhibitor, Pralsetinib, in Healthy Subjects
Favorite
B
149
Bioequivalence Safe Space Assessment of Molnupiravir & NHC Using Physiologically Based Biopharmaceutics Modeling
Favorite
015
Biosimilar Uptake & Cost Savings Analysis Before & After Implementation of a Pharmacist-driven Substitution Program Within a National Community Oncology Network: One Year Follow-up
Favorite
C
061
Cefazolin Removal Via Pediatric Continuous Renal Replacement Therapy: An Ex-vivo Analysis
Favorite
042
Characterizing the Effect of Recombinant Human Hyaluronidase on Subcutaneous Pharmacokinetics of Drugs
Favorite
129
Clinical & Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib as a Perpetrator of Drug-Drug Interactions in Cancer Patients
Favorite
127
Clinical & Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib as a Victim of Drug-Drug Interactions in Cancer Patients
Favorite
146
Clinical PK Sampling Strategies, Precise Accurate Estimates of Population Clearance. Is Trough Sampling Enough? Practical NOT Optimal Sampling
Favorite
036
Clinical Validation of Two Volumetric Absorptive Microsampling Devices to Support Home-based Therapeutic Drug Monitoring of Immunosuppression in Kidney Transplantation
Favorite
180
Comparative Structure, In Vitro Efficacy & Pharmacokinetics of HSK3486 & Propofol
Favorite
081
Country Contribution of Investigators to Pivotal Clinical Trials & their Primary Publications of New Drugs Approved by the US Food & Drug Administration
Favorite
D
038
Development & Qualification of a Population Model of Gene Therapy for the Treatment of Hemophilia A & Comparison With FVIII Therapies
Favorite
010
Development of a Mechanistic-Physiologically Based Pharmacokinetic Platform Model to Guide Adult & Pediatric Dosing for Bispecific T Cell Engagers through Intravenous & Subcutaneous Administration
Favorite
108
Development of a Mechanistic-Physiologically Based Pharmacokinetic Platform Model to Guide Adult & Pediatric Dosing for Bispecific T Cell Engagers through Intravenous & Subcutaneous Administration
Favorite
115
Development of Electronic Patient Reported Outcome for Symptom Assessment in Severe Fever With Thrombocytopenia Syndrome Patients in Routine Clinical Practice
Favorite
088
Development, Verification & Application of Physiologically-based Pharmacokinetic Model to Evaluate the CYP3A4-mediated Drug-Drug Interactions Potential of Omaveloxolone
Favorite
026
Differential Induction Effects of Prednisone & Prednisolone on Mycophenolic Acid Intrinsic Clearance
Favorite
113
Digital Twin-Based Metaverse Clinical Trial Space: From Making Clinical Trials More Accessible to Using It as a New Clinical Trial Tool
Favorite
156
Dimethoxycurcumin Induces Global DNA Hydroxymethylation & Increases the Activity of TET Enzymes in Leukemia Cells
Favorite
007
Drug & Dietary Supplement Exposures During Pregnancy & Lactation in the United States Between 2011-2022
Favorite
105
Drug & Dietary Supplement Exposures During Pregnancy & Lactation in the United States Between 2011-2022
Favorite
051
Drug Discovery of PPAR (Peroxisome Proliferator Activated Receptor) Agonists as Promising Treatment for Alzheimer's Disease
Favorite
175
Drug-Drug Interaction (DDI) Study of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degrader Bavdegalutamide in Combination With the CYP3A4 Inhibitor Itraconazole in Healthy Volunteers
Favorite
030
Drug-Drug Interaction of Celecoxib With Navitoclax in Subjects With Myeloproliferative Neoplasms (MPN)
Favorite
E
154
Early Clinical Pharmacokinetic/Pharmacodynamic Modeling & Simulation of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, to Support First-in-Disease Clinical Trials in Autoimmune Glomerulonephritis & Cytopenias
Favorite
032
Effect of Carbamazepine, a CYP29C & 3A4 Inducer, on the Pharmacokinetics of Erdafitinib (Balversa®): A Phase I Drug-Drug Interaction Study in Healthy Adult Participants
Favorite
084
Effect of Hepatic Impairment on Single Dose Pharmacokinetics (PK) of Lazertinib
Favorite
171
Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open-Label, Phase 1 Study
Favorite
021
Efficacy of Bulevirtide as Monotherapy for Chronic Hepatitis D (CHD): Week 48 Results from an Integrated Analysis
Favorite
117
Efficacy, Safety, Pharmacokinetic (PK) & Pharmacodynamic (PD) Support for Talquetamab Weekly (QW) & Biweekly (Q2W) Dosing in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Analyses From MonumenTAL-1
Favorite
151
Evaluating Clinical Impact of Hormonal Contraceptive Drug-Drug Interactions/Obesity on Ovulation Rate & Pearl Index Using Integrated Physiologically-based Pharmacokinetic Modeling & Model Based Meta-Analysis Approach
Favorite
126
Evaluation of Talquetamab Drug-Drug Interaction Potential as a Result of Cytokine Release Syndrome in Patients With Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
Favorite
197
Evaluation of the Impact of Physiological Changes of Pregnancy & Cancer on Oncology Drug Pharmacokinetics Towards Implementing a “Cancer-Pregnancy Physiologically Based Pharmacokinetic (PBPK) Population Model”
Favorite
139
Examining #Pharmacovigilance in the Era of COVID-19: A Hashtag Analysis Study
Favorite
F
019
FDA Trends for Accelerated Drug Approvals in Oncology Indications
Favorite
090
Flushing Out Translational Excretion Data: How Well Do Nonclinical ADME Results Predict Clinical Findings?
Favorite
G
122
Genome-Wide Mapping of 5-methylcytosine and 5-hydroxymethylcytosine in Acute Myeloid Leukemia Primary Samples & Cord Blood Cells
Favorite
001
Genomic Risk Factors of Vincristine-Induced Peripheral Neuropathy
Favorite
H
111
How to Use Digital Twin Technology in Clinical Trial
Favorite
I
119
Impact of Inflammatory Diseases on the Pharmacokinetics of Therapeutic Proteins
Favorite
014
Impact of Solubility & Dissolution Performance on Bioequivalence Recommendations for Immediate-Release Locally Acting Gastrointestinal Drug Products
Favorite
013
Impacts of Bio-Batch Adequacy on Bioequivalence Assessment of Generic Drug Product Applications
Favorite
080
Improving Administration Method Consistency of Product-Specific Guidances for Chewable Tablets & Tablet Products With Chewing in Labeling
Favorite
033
Improving the Working Models for Drug-Drug Interactions: Impact on Preclinical & Clinical Drug Development
Favorite
178
In Silico Physiologically Based Pharmacokinetic Model of the Effect of Hepatic Impairment on Trofinetide Exposures
Favorite
029
In Vitro & In Vivo Assessment on Endogenous Biomarkers for Studying Renal Transporter (OCT2, MATE1/2-K) Mediated Drug Interaction & Disease Impact Consideration in Novel Endogenous Biomarker, N1-Methyladenosine: A Systematic Review
Favorite
006
Infant & Adult VRC07-523LS Population Pharmacokinetic Modeling to Predict HIV Prevention in Breastfed Infants
Favorite
104
Infant & Adult VRC07-523LS Population Pharmacokinetic Modeling to Predict HIV Prevention in Breastfed Infants
Favorite
152
Inhibition of the Complement Alternative Pathway in Healthy Subjects by an Oral Factor D Inhibitor
Favorite
131
Intramuscular Triamcinolone Acetonide (Kenalog®): A Conundrum Amongst Corticosteriods
Favorite
017
Intranasal Human Abuse Potential of PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug
Favorite
005
Investigating Tacrolimus Population Pharmacokinetics in Adult Hispanic Renal Transplant Recipients
Favorite
103
Investigating Tacrolimus Population Pharmacokinetics in Adult Hispanic Renal Transplant Recipients
Favorite
101
Is the Current Dosing Regimen of Ropivacaine Administered through Erector Spinae Plane Blocks Safe?
Favorite
003
Is the Current Dosing Regimen of Ropivacaine Administered through Erector Spinae Plane Blocks Safe?
Favorite
008
Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework
Favorite
106
Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework
Favorite
K
190
Kick-starting Reporting of Pharmacokinetic Results With Simulated Concentration-Time Data
Favorite
L
134
Lack of Consistency in Pharmacokinetic Drug-Drug Interaction Management With CYP3A Substrates in Phase II/III Clinical Trials: A Call for Regulatory Guidance
Favorite
137
Landscape Analysis of Adverse Events & Dose Intensity for FDA Approved Oncology Small Molecules
Favorite
132
Limited Potential for Interactions Between Trofinetide, a New Treatment for Rett Syndrome, & Drugs Metabolized By CYP3A4
Favorite
M
135
Methods to Assess QT/QTc Prolongation in Oncology Clinical Development: A Landscape Analysis of Approved Oncology Therapeutics
Favorite
193
Microdosed Yohimbine as CYP2D6 Probe Drug in Pediatric Heart Patients Aged 6 Months to 6 Years
Favorite
002
Model-based Investigation on Allometric Scaling in Pediatric PK: The Effects of Sample Size, Sampling Scheme & Age Range
Favorite
100
Model-based Investigation on Allometric Scaling in Pediatric PK: The Effects of Sample Size, Sampling Scheme & Age Range
Favorite
046
Model-Based Meta-Analyses to Compare Inhaled Fluticasone Furoate & Vilanterol Systemic Exposures in Japanese & Non-Japanese Pediatric Population With Asthma
Favorite
121
Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases: An Overview of Clinical Pharmacology Contributions & Opportunities
Favorite
N
165
No Clinically Meaningful Pharmacokinetic Drug-Drug Interaction between Berotralstat & the Progestin Oral Contraceptive Desogestrel
Favorite
155
Novel Gut-Brain Axis for Craving, Alcohol Withdrawal & Withdrawal-Associated Depression in Patients With Alcohol Use Disorder
Favorite
O
016
Oral Human Abuse Potential of PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug
Favorite
P
130
PBPK Model Development & Simulations to Predict Drug-Drug Interactions of Atogepant
Favorite
025
Pediatric Drug Development Programs for Locally Acting Drug-Device Combination Products
Favorite
123
Pharmacogenomics of β-lactam Antibiotic-induced Severe Cutaneous Adverse Reactions
Favorite
012
Pharmacogenomics of L-Asparaginase-induced Pancreatitis in Pediatric Patients With Acute Lymphoblastic Leukemia
Favorite
173
Pharmacokinetic & Pharmacodynamic Modeling of QY201, a JAK1/TYK2 Inhibitor, in Healthy Chinese Adults
Favorite
031
Pharmacokinetic Drug Interaction Between Nipocalimab & Fremanezumab in Healthy Subjects
Favorite
059
Pharmacokinetics & Immunogenicity of Combination Therapy of Guselkumab & Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis
Favorite
124
Pharmacokinetics & Pharmacodynamics of Casirivimab & Imdevimab in Pregnant Outpatients With COVID-19
Favorite
125
Pharmacokinetics & Pharmacodynamics of Casirivimab &Imdevimab in Pediatric Outpatients With COVID-19
Favorite
083
Pharmacokinetics & Safety of Navitoclax in Hepatic Impairment
Favorite
183
Pharmacokinetics & Viral Shedding of an Oncolytic Virus (MEDI5395) in a Phase 1 Clinical Study
Favorite
022
Pharmacokinetics of a Fixed-dose Combination of Dapagliflozin 10 mg & Sitagliptin 100 mg for the Treatment of Type 2 Diabetes Mellitus
Favorite
189
Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer
Favorite
182
Pharmacokinetics of RBN-3143 in Healthy Adults, A Novel Mono (ADP-Ribose) Polymerase-14 (PARP14) Inhibitor
Favorite
065
Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device or Prefilled Syringe
Favorite
076
Pharmacokinetics, Metabolism, Excretion & Mass Balance of 14C-HZN-825, a LPAR-1 Antagonist, in Healthy Male Subjects
Favorite
167
Pharmacokinetics, Pharmacodynamics & Exposure- Response for Neurotoxicity Adverse Events in a Phase Ib/II CARTITUDE-1 Open-Label Study
Favorite
071
Pharmacokinetics, Safety & Tolerability of HZN-825, a LPAR-1 Antagonist, Following Single & Multiple Doses in Healthy Japanese Subjects
Favorite
179
Phase 1 Study Evaluating the Bioequivalence of the Dispersible Final Market Image Macitentan Tablet & the Opsumit® Tablet in Fasted Conditions
Favorite
148
PK/PD Modeling of Progranulin Elevation in Blood & CSF to Support AL101 Dose Selection & Phase 2 Study Design
Favorite
048
Population Modeling Analyses of Sotatercept Pharmacokinetics, Safety & Efficacy in Healthy Participants & Patients With Pulmonary Arterial Hypertension
Favorite
056
Population Pharmacokinetic Analysis of Tucatinib in Healthy Subjects & Subjects With HER2+ Metastatic Breast Cancer or Metastatic Colorectal Cancer
Favorite
057
Population Pharmacokinetic Model Development of Autologous CD30.CAR-T Cells in Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Patients
Favorite
069
Population Pharmacokinetic Model of Delta-9-Tetrahydrocannabinol (THC) & Metabolites in Healthy Adults Following Single Oral Dose
Favorite
186
Population Pharmacokinetic Modeling of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Solid Tumors
Favorite
055
Population Pharmacokinetic Modeling to Assess the Impacts of Clinical Variables on Mycophenolate Total Body Clearance in Pediatric Kidney Transplant Recipients
Favorite
047
Population Pharmacokinetic Modeling to Establish Exposure Equivalence Between Two Formulations of Albuterol Dry Powder Inhaler
Favorite
184
Population Pharmacokinetic Modelling of RP-6306, a Novel PKMYT1 Inhibitor, in Cancer Patients from a Phase 1 Dose Escalation Study
Favorite
072
Population Pharmacokinetic Modelling to Confirm Weight-Based Banded Dosing & Exposure-Response Efficacy Analyses to Support Trofinetide Treatment in Rett Syndrome
Favorite
058
Population Pharmacokinetic Modelling to Predict Trofinetide Exposure & Exposure-Response Safety Analyses in Girls With Rett Syndrome Aged 2–4 Years
Favorite
168
Population Pharmacokinetic/Pharmacodynamic Analysis of MDM2 Inhibitor Navtemadlin (KRT-232) in Combination with Decitabine in a Phase 1 Dose Escalation Study of Subjects With Acute Myeloid Leukemia
Favorite
142
Population Pharmacokinetic-Pharmacodynamic (PKPD) Modeling Analyses of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Solid Tumors
Favorite
066
Population Pharmacokinetics & Exposure-Response Analysis of Durvalumab With Gemcitabine & Cisplatin in Patients With Advanced Biliary Tract Cancer
Favorite
075
Precision Dosing in Critically Ill Patients: A Voriconazole Case Study
Favorite
041
Predicting Clinical PK/PD & Impacts of Organ Impairment to Support Clinical Development of siRNA-based Therapeutics Using a Mechanistic Physiologically Based Pharmacokinetic & Pharmacodynamic (PBPK-PD) Platform Model
Favorite
110
Predicting Pregnancy Population Pharmacokinetics Using Machine Learning Algorithms
Favorite
196
Predictive Physiologically Based Pharmacokinetic (PBPK) Model Suggests Minimal Drug-Drug Interaction (DDI) Between PPARδ Agonist Mavodelpar (REN001) & Rosuvastatin
Favorite
128
Probing CYP3A4 Drug Metabolism Change in Patients With Obesity Undergoing Weight-Loss Using a Micro-Dose of Midazolam
Favorite
086
Probing Gastric Emptying & Drug Metabolism Changes in Patients With Obesity Undergoing Weight-Loss Using a Cocktail Containing Acetaminophen, Caffeine & Omeprazole
Favorite
153
Proof of Mechanism & Pharmacodynamic Fingerprinting; Relating 7,000 Protein Measurements to Disease & Pharmacology: An Example Using the Impact of Peginterferon on Influenza A Pathway
Favorite
195
Protamine Protects Against Vancomycin Induced Kidney Injury in a Translational Rat Model
Favorite
R
150
Real-World Application of Physiologically Based Pharmacokinetic Modeling (PBPK) in Support of Decision-Making During Drug Discovery; Guidance & Recommendations for the Utility of PBPK Impact on Candidate Selection & Human Pharmacokinetic Prediction Through Case Examples
Favorite
181
Relative Bioavailability & Food Effect of Phase 2 Formulations of Zimlovisertib in Healthy Participants
Favorite
039
Retrospective Time to Dose Modification Evaluation of Apalutamide
Favorite
164
Riluzole in Acute Spinal Cord Injury Study (RISCIS) With the Bayesian Approach to Overcome Small Sample Size & Inter-subject Variability
Favorite
S
157
Self-perceived Differential Effects of Kratom (Mitragyna speciosa Korth) “Strains” Do Not Correlate With Alkaloid Content
Favorite
043
Semi-Mechanistic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients
Favorite
087
Simulating (R)-omeprazole & (S)-omeprazole Pharmacokinetics in Obese & Post-bariatric Surgery Patients by Physiologically based Pharmacokinetic Modeling
Favorite
159
Statin Prescribing Trends, Utilization & Expenditure in English Hospitals: A Retrospective Study Using a Large National Database
Favorite
078
Survey of Bioequivalence Data of Abbreviated New Drug Applications of Narrow Therapeutic Index Drug Products
Favorite
082
Swallowability of Solid Oral Drug Products in Regulatory Submissions: Patient-Specific Features, Product Physical Attributes & Clinical Swallowability Study Designs
Favorite
T
077
TABLET: Relative Bioavailability & Bioequivalence Study of Niraparib Tablets & Capsules in Patients With Advanced Solid Tumors
Favorite
177
The Effect of a High-Fat Meal on the Pharmacokinetics of Dordaviprone in Healthy Adult Participants
Favorite
063
The Effect of Administering Dordaviprone as Capsule Contents Mixed With Applesauce or Dissolved in Gatorade on the Pharmacokinetics of Dordaviprone in Healthy Adult Participants
Favorite
166
The Effect of Food & the Proton Pump Inhibitor (PPI) Esomeprazole on the Single-Dose Pharmacokinetics (PK) & Safety of ARV-766, a PROteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degrader, in Healthy Volunteers
Favorite
163
The Effect of Food & the Proton Pump Inhibitor (PPI) Esomeprazole on the Single-Dose Pharmacokinetics (PK) and Safety of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degrader Bavdegalutamide in Healthy Volunteers
Favorite
074
The Effect of Itraconazole, a Strong CYP3A4 Inhibitor, on the Pharmacokinetics of Dordaviprone in Healthy Adult Participants
Favorite
169
The Effect of Rabeprazole, a Proton-Pump Inhibitor, on the Pharmacokinetics of Dordaviprone in Healthy Adult Participants
Favorite
062
The MILK Study: Investigating Pharmacokinetics of Low-calorie Sweeteners in Mother Infant Dyads
Favorite
044
The Role of Exposure-Response Analyses in Determination of Recommended Dose for Expansion in a Phase I/Ib Study of NIZ985 Alone & in Combination With Spartalizumab in Cancer Patients
Favorite
089
The Utilization of Pharmacokinetic/Pharmacodynamic (PK/PD) Model-based Analysis of Myelosuppression in Clinical Trials: Analysis from Adavosertib Clinical Studies
Favorite
U
004
Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry for the Simultaneous Detection of Conjugated Metabolites of Indoxyl & p-Cresol for Toxicokinetic Investigations
Favorite
102
Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry for the Simultaneous Detection of Conjugated Metabolites of Indoxyl & p-Cresol for Toxicokinetic Investigations
Favorite
037
Understanding Methotrexate Concentrations & Associated Toxicities to Guide Supportive Care in Patients With Osteosarcoma
Favorite
192
Unraveling the Roadmap for Amikacin TDM in Critically Ill Cancer Patients
Favorite
V
085
Vancomycin Associated Nephrotoxicity & Clinical Outcomes Assessment in Geriatric Empiric Dosing Strategies (VANCO-AGED)
Favorite
